The estimated Net Worth of Jonathan C Javitt is at least $279 Thousand dollars as of 27 August 2008. Jonathan Javitt owns over 40,000 units of Brainstorm Cell Therapeutics stock worth over $268,800 and over the last 17 years Jonathan sold BCLI stock worth over $10,000.
Jonathan has made over 1 trades of the Brainstorm Cell Therapeutics stock since 2008, according to the Form 4 filled with the SEC. Most recently Jonathan sold 40,000 units of BCLI stock worth $10,000 on 27 August 2008.
The largest trade Jonathan's ever made was selling 40,000 units of Brainstorm Cell Therapeutics stock on 27 August 2008 worth over $10,000. On average, Jonathan trades about 13,333 units every 0 days since 2007. As of 27 August 2008 Jonathan still owns at least 960,000 units of Brainstorm Cell Therapeutics stock.
You can see the complete history of Jonathan Javitt stock trades at the bottom of the page.
Jonathan's mailing address filed with the SEC is C/O BRAINSTORM CELL THERAPEUTICS INC., 110 EAST 59TH STREET, NEW YORK, NY, 10022.
Over the last 21 years, insiders at Brainstorm Cell Therapeutics have traded over $1,899,994 worth of Brainstorm Cell Therapeutics stock and bought 1,713,254 units worth $1,535,874 . The most active insiders traders include Corp. Accbt, Mike Frankenberger, and International Holdings Ltd..... On average, Brainstorm Cell Therapeutics executives and independent directors trade stock every 145 days with the average trade being worth of $206,459. The most recent stock trade was executed by Ibrahim B. Dagher on 19 July 2024, trading 63,000 units of BCLI stock currently worth $22,050.
brainstorm cell therapeutics inc. (nasdaq:bcli), is a biotechnology company developing innovative, autologous stem cell therapies for highly debilitating neurodegenerative disorders such as als (lou gehrig's disease), multiple sclerosis (ms) and parkinson’s disease (pd). these diseases have limited treatment options and as such represent unmet medical needs. nurown™ is brainstorm’s proprietary process for the propagation and differentiation of adult, autologous mesenchymal stem cells (msc) into neurotrophic factor (ntf)-secreting cells, and the transplantation of these specialized cells at or near the affected tissue site. our platform technology essentially converts mscs into living drug delivery system for ntfs. we have obtained proof-of-concept in a variety of animal models of neurodegenerative diseases, including parkinson's, huntington's, als, ms, and peripheral nerve injury. we have completed two single-arm clinical trials in als patients, conducted in israel, which have demonstr
Brainstorm Cell Therapeutics executives and other stock owners filed with the SEC include: